Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

AbbVie: M16-186 Ph1b Venetoclax and Alvocidib in R/R AML (Leukemia) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if the study drugs, Venetoclax and Alvocidib, can be safely combined for use in patients with relapsed/refactory AML.
What is the Condition Being Studied?
Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who Can Participate in the Study?

Adults who:
- Have a diagnosis of R/R AML
- Do not have central nervous system leukemia
- Do not have severe chronic obstructive pulmonary disease (COPD) with hypoxemia
- Do not have any prior allogeneic stem cell transplant within 6 months of getting the study drug and no requirement for graft versus host therapy
- Do not have a history of taking alvocidib or any other CDK9 inhibitor
- Do not have any known gastrointestinal disorders
- Do not have an active, uncontrolled infection
- Do not have a known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

Age Group

What is Involved?

If you choose to join this study, you will:
- Have a screening visit to make sure it safe for you to be in this study
- Take Venetoclax once daily by mouth for 28 days and Alvocidib that will be given by iv infusion on day 1, 2 and 3 of all cycles
- Have a follow-up visit that will include follow up exams and other tests every month for 1 year

Study Details

Full Title
Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00091269
NCT: NCT03441555
Phase I
Contact the Duke Recruitment Innovation Center